title: Prognostic Evaluation of Nasopharyngeal Carcinoma with Bone-Only Metastasis after Therapy.
abstract: OBJECTIVE
  To evaluate the prognosis of nasopharyngeal carcinoma (NPC) patients who developed bone-only metastasis after primary treatment and the stratification of these patients into different risk groups based on independent prognostic factors.
  
  
  METHODS
  Eighty NPC patients who developed bone-only metastasis after definitive radiotherapy from October 2005 to December 2010 were enrolled. All these patients received palliative treatment for bone metastasis, including chemotherapy and/or radiotherapy. Clinical features, treatment modality, and laboratory parameters were examined with univariate and multivariate analyses.
  
  
  RESULTS
  The median follow-up time was 15.5 months (range, 2-67 months) for the whole cohort. The median overall metastatic survival (OMS) time and the 2-year estimate OMS rate were 26.5 months and 52%, respectively. Multivariate analysis indicated that patients with short metastases-free interval, multiple bone metastases sites, high serum lactic dehydrogenase levels, and treated with radiotherapy or chemotherapy alone had significantly worse outcomes. Patients were stratified into three different risk groups based on the number of adverse factors present. The OMS curves of the three groups were all significantly different (p<0.001).
  
  
  CONCLUSIONS
  Severl prognostic factors were found to be associated with worse outcomes. According to the number of adverse factors present, bone-only metastasis patients can be stratified into three risk groups with significantly different prognoses. Such grouping may help in improving the design of clinical trials and in guiding individualized treatment for NPC patients with bone-only metastasis.
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Tianzhu
authors.initials: T
authors.lastname: Lu
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Qiaojuan
authors.initials: Q
authors.lastname: Guo
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Cui
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Zhuhong
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Shaojun
authors.initials: S
authors.lastname: Lin
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Luying
authors.initials: L
authors.lastname: Xu
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Lin
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China.
authors.forename: Jingfeng
authors.initials: J
authors.lastname: Zong
authors.affiliation: Provincial Clinical College, Fujian Medical University, Fuzhou, Fujian, China.|Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.|Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, China. panjianji@126.com.
authors.forename: Jianji
authors.initials: J
authors.lastname: Pan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D002277:Carcinoma; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
keywords: Nasopharyngeal neoplasm; neoplasm metastasis; prognosis